Ask about Melanotan II

Get a grounded answer across clinical evidence, community patterns, and risks.

Ask AI →

Melanotan II

Also known as: MT-2, MT-II, Melanotan 2

Cosmetic Research Compound

Synthetic melanocortin receptor agonist

Mechanism of Action

Non-selective melanocortin agonist that stimulates melanogenesis (tanning) and affects libido and appetite. Not approved; notable safety concerns (nausea, blood-pressure and melanocytic/mole changes).

Note: Not approved for human use; community/cosmetic use

367
Community Posts
162
Users Discussing
3
Research Articles
0

Reported Outcomes

Clinical grade reflects published research; Community grade reflects user reports (n=367).

Sleep Quality

Effects on sleep quality

Clinical: D
Community: B
24% (58)
Energy Levels

Changes in energy and fatigue levels

Clinical: D
Community: B
13% (29)
Mental/Mood

Effects on mood and cognitive function

Clinical: D
Community: B
7% (19)

Who Discusses Melanotan II

From community reports with demographic data.

Gender (limited data)

Male 61%
Female 39%

n=18

Side Effects

Limited data

Based on 23 user reports (n=23). Frequency indicates how often each was mentioned.

Common (>5%)

Insomnia
Mild 3 reports 11.5%
Nausea
Mild 3 reports 11.5%
Injection Site Stinging
Mild 2 reports 7.7%
Flushing
Mild 2 reports 7.7%

Uncommon (1-5%)

Orange Appearance
Mild 1 reports 3.8%
Extreme Tan (From Melanotan Ii)
Mild 1 reports 3.8%
Frequent Bowel Movements
Mild 1 reports 3.8%
Water Retention
Mild 1 reports 3.8%
Plateau
Mild 1 reports 3.8%
Fatigue
Mild 1 reports 3.8%
Heartburn
Mild 1 reports 3.8%

Risks & Warnings

Important safety considerations based on clinical data and community reports.

!

Psychiatric Effects

4 mentions

Monitor for mood changes. Report any concerning psychiatric symptoms to healthcare provider.

i

Injection Site Reactions

11 mentions

Local reactions are common and usually mild. Rotate injection sites.

Dosing

Standard Protocol

Starting Dose
Community protocols vary (low microgram loading); limited data
Titration
No established protocol
Half-life
Hours
Administration
Subcutaneous injection

Community Dosing Patterns

Based on 26 mentions

Community-reported patterns, not medical advice.

200mcg daily
2
0.5mg daily
2
250mcg
2
500mcg
2
100mcg 2x/week
1

Research

3
Total Articles
0 0

Key Studies

Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment Clinical Trial

Curr Issues Mol Biol (2023)

Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide Preclinical

Physiol Behav (2020)

Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression Preclinical

Mol Metab (2023)

Commonly Stacked With

From community members' documented stacks involving Melanotan II.

Retatrutide 7 stacks (41.2%)
Tirzepatide 6 stacks (35.3%)
GHK-Cu 4 stacks (23.5%)
NAD+ 3 stacks (17.6%)
KPV 3 stacks (17.6%)

Switching Patterns

Based on 28 discussions about switching to or from Melanotan II.

→ Switching FROM

Tirzepatide 3 mentions
Retatrutide 3 mentions
BPC-157 3 mentions

Users who switched to Melanotan II

← Switching TO

GHK-Cu 5 mentions
Retatrutide 3 mentions

Users who switched from Melanotan II